How to get a GLP-1 covered by insurance

Coverage for these medicines is inconsistent, and a denial is often about which box was ticked rather than whether you need the drug. This page is the practical sequence.

Nothing here is a promise that your plan will pay. It is what to establish, in what order, and what to do when the answer is no.

First, the distinction that decides a lot of claims

Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for chronic weight management.

Ozempic and Wegovy contain the same molecule, semaglutide. Mounjaro and Zepbound contain the same molecule, tirzepatide. In both pairs the brands are not interchangeable, because the approved use and the dosing differ.

Many plans cover the diabetes indication and exclude weight management. So the single most common reason a claim behaves unexpectedly is that the brand on the prescription does not match the benefit being billed.

Before anything else, establish which brand you are prescribed and for which indication.

Second, find out what your plan actually says

Call the number on your insurance card and ask, in these words:

• Does my plan cover medicines for chronic weight management, or only for type 2 diabetes?
• Is prior authorisation required, and what are the criteria?
• Is there a step therapy requirement, meaning I must try something else first?
• Is the specific brand on my formulary, and at which tier?
• Is there a quantity limit?

Ask for the answer in writing or for a reference number. Formulary decisions change annually.

Third, prior authorisation

If weight management drugs are covered at all, prior authorisation is usual. It means your clinician submits documentation before the plan will pay.

Plans publish their criteria. They commonly ask for things like a documented body mass index threshold, weight related conditions, and evidence of prior attempts at weight management. Your clinician's office usually handles the submission, but they can only submit what is in your record, which is why the appointment where you discuss history matters.

Two practical points. Ask what the criteria are before the appointment, so the relevant history is actually discussed. And ask how long the authorisation lasts, because many require renewal.

Fourth, if you are denied

A denial is not the end, and appeal rates are not trivial.

Ask for the specific reason in writing. There is a difference between "not a covered benefit," which is a plan design question, and "criteria not met," which is a documentation question. The second is often fixable.

If criteria were not met, find out which one, and whether the missing evidence exists in your record.

If step therapy is the block, ask what counts as a trial and whether anything you have already done qualifies.

Use the internal appeal, then the external review if your plan and state provide one. Your clinician can often submit a letter of medical necessity.

Fifth, if it is genuinely not covered

Then the question moves to the other three routes.

Medicare Part D beneficiaries should check the Medicare GLP-1 Bridge, which gives certain GLP-1 drugs at fifty dollars a month through 31 December 2027. From 2027 the BALANCE model extends negotiated pricing to participating Part D plans and state Medicaid agencies, with a fifty dollar cap in the initial coverage phase.

Medicaid varies by state, both in whether these drugs are covered and on what terms.

No coverage at all points to the federal cash prices on TrumpRx.gov, which requires a prescription you already hold.

Timing, because it is seasonal

If your plan simply does not cover weight management medicines, the moment to change that is enrollment.

• Medicare Annual Enrollment: 15 October to 7 December 2026, for coverage starting 1 January.
• Marketplace open enrollment for 2027 coverage on the federal platform: 1 November to 15 December 2026. Note this window is shorter than in previous years.

If a plan change is the answer, that is a decision with a deadline on it.

What not to do

Do not describe your situation inaccurately to obtain coverage. Beyond the obvious, it puts your clinician in a difficult position and can invalidate a claim later.

Do not assume a denial applies to every product. A different brand or indication may be handled differently under the same plan.

What to ask

• Which brand am I prescribed, and for which approved indication?
• Does my plan cover chronic weight management at all?
• What exactly are the prior authorisation criteria, and does my record meet them?
• If denied, was it a benefit exclusion or a criteria failure?
• Given the enrollment dates, is changing plans the actual answer?

Sources

• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• Centers for Medicare and Medicaid Services, BALANCE Model
• Centers for Medicare and Medicaid Services, key dates for the Health Insurance Marketplace
• Medicare.gov, Medicare Open Enrollment, 15 October to 7 December
• Medicaid.gov, prescription drug coverage and state flexibility
• The White House, Fact Sheet on the launch of TrumpRx.gov, 6 February 2026

How we verify: see /how-we-verify.

Keep reading

All four ways to pay compared, at /guides/how-to-pay-for-glp1.

Why the Ozempic and Wegovy distinction changes what your plan pays, at /guides/ozempic-vs-wegovy.